Mibefradil- and ω-conotoxin GVIA-induced inhibition of noradrenaline release from the sympathetic nerves of the human heart

被引:36
作者
Göthert, M [1 ]
Molderings, GJ [1 ]
机构
[1] Univ Bonn, Inst Pharmakol & Toxikol, D-53113 Bonn, Germany
关键词
mibefradil; omega-conotoxin GVIA; nifedipine; calcium channels; N-type Ca2+ channels; L-type Ca2+ channels; human atrial appendages; sympathetic nerves;
D O I
10.1007/PL00005130
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Segments of human right atrial appendages preincubated with [3H]noradrenaline and superfused with physiological salt solution containing desipramine and corticosterone were used to determine the effects of mibefradil, omega-conotoxin (omega-CTx) GVIA and nifedipine on tritium overflow evoked by transmural electrical stimulation. Mibefradil (which predominantly blocks T-type, and at lower potency also N-type, Ca2+ channels) at concentrations of 0.3-3 mu M reduced the electrically evoked tritium overflow in a reversible and concentration-dependent manner (IC50%: 1 mu M), whereas 0.1-10 mu M nifedipine (a selective blocker of L-type channels) was ineffective. The evoked tritium overflow was almost abolished by 0.2 mu M omega-CTx GVIA. (a selective blocker of N-type channels), It is concluded that noradrenaline release from cardiac sympathetic nerves is triggered by Ca2+-influx via N-type, but not L-type, Ca2+ channels and that the inhibitory effect of mibefradil at clinically relevant concentrations on noradrenaline release is probably due to its blocking action on N-type Ca2+ channels. This property of mibefradil is unique among the therapeutically applied Ca2+ channel blockers and may contribute to the slight negative chronotropic effect of the drug in vivo.
引用
收藏
页码:860 / 863
页数:4
相关论文
共 16 条
[1]   EFFECTS OF THE NEW CALCIUM-ANTAGONIST MIBEFRADIL (RO-40-5967) ON EXERCISE DURATION IN PATIENTS WITH CHRONIC STABLE ANGINA-PECTORIS - A MULTICENTER, PLACEBO-CONTROLLED STUDY [J].
BAKX, ALM ;
VANDERWALL, EE ;
BRAUN, S ;
EMANUELSSON, H ;
BRUSCHKE, AVG ;
KOBRIN, I .
AMERICAN HEART JOURNAL, 1995, 130 (04) :748-757
[2]   Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967) - A new generation of calcium antagonists? [J].
Bernink, PJLM ;
Prager, G ;
Schelling, A ;
Kobrin, I .
HYPERTENSION, 1996, 27 (03) :426-432
[3]  
BEZPROZVANNY L, 1995, MOL PHARMACOL, V48, P540
[4]   Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: A multicenter placebo-controlled study [J].
Braun, S ;
vanderWall, EE ;
Emanuelsson, H ;
Kobrin, I .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 27 (02) :317-322
[5]   RO 40-5967 - A NEW NONDIHYDROPYRIDINE CALCIUM-ANTAGONIST [J].
CLOZEL, JP ;
OSTERRIEDER, W ;
KLEINBLOESEM, CH ;
WELKER, HA ;
SCHLAPPI, B ;
TUDOR, R ;
HEFTI, F ;
SCHMITT, R ;
EGGERS, H .
CARDIOVASCULAR DRUG REVIEWS, 1991, 9 (01) :4-17
[6]   Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine [J].
Furukawa, T ;
Nukada, T ;
Suzuki, K ;
Fujita, Y ;
Mori, Y ;
Nishimura, M ;
Yamanaka, M .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 121 (06) :1136-1140
[7]  
GOTHERT M, 1997, N-S ARCH PHARMACOL, V356, pR6
[8]  
HAUSTEIN KO, 1990, INT J CLIN PHARM TH, V28, P458
[9]   Involvement of different calcium channels in K+- and veratridine-induced increases of cytosolic calcium concentration in rat cerebral cortical synaptosomes [J].
Meder, W ;
Fink, K ;
Göthert, M .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 356 (06) :797-805
[10]   ANTAGONISTS OF NEURONAL CALCIUM CHANNELS - STRUCTURE, FUNCTION, AND THERAPEUTIC IMPLICATIONS [J].
MILJANICH, GP ;
RAMACHANDRAN, J .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1995, 35 :707-734